NCT05169580 – A Phase 1 Open-Label, Multiple Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)

Last modified: October 22, 2024

You are here:

Find a Clinical Trial
Phase 1
NCT05169580 – A Phase 1 Open-Label, Multiple Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FTX-6058 in participants with sickle cell disease.

Was this article helpful?